Anti-angiogenic Abs, such as the anti-VEGF bevacizumab and anti-VEGFR2 ramucirumab, have been shown to block VEGF signaling, “normalizing” the tortured, disorganized vasculature typical of advanced cancers, and helping shift the immune microenvironment from one that is immunosuppressive to one that promotes immune function, tumor recognition, and DC maturation (41). Here, VEGFA is linked to neoplasm.